204 related articles for article (PubMed ID: 11204811)
1. Diagnostic value of plasma chromogranin A in neuroendocrine tumours.
Tomassetti P; Migliori M; Simoni P; Casadei R; De Iasio R; Corinaldesi R; Gullo L
Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):55-8. PubMed ID: 11204811
[TBL] [Abstract][Full Text] [Related]
2. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
5. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
6. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
7. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
Nehar D; Lombard-Bohas C; Olivieri S; Claustrat B; Chayvialle JA; Penes MC; Sassolas G; Borson-Chazot F
Clin Endocrinol (Oxf); 2004 May; 60(5):644-52. PubMed ID: 15104570
[TBL] [Abstract][Full Text] [Related]
8. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours.
Stridsberg M; Eriksson B; Lundqvist G; Skogseid B; Wilander E; Oberg K
Regul Pept; 1995 Jan; 55(2):119-31. PubMed ID: 7754100
[TBL] [Abstract][Full Text] [Related]
9. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
10. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1.
Granberg D; Stridsberg M; Seensalu R; Eriksson B; Lundqvist G; Oberg K; Skogseid B
J Clin Endocrinol Metab; 1999 Aug; 84(8):2712-7. PubMed ID: 10443665
[TBL] [Abstract][Full Text] [Related]
11. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas.
Bashir S; Gibril F; Ojeaburu JV; Asgharian B; Entsuah LK; Ferraro G; Crafa P; Bordi C; Jensen RT
Aliment Pharmacol Ther; 2002 Jul; 16(7):1367-82. PubMed ID: 12144588
[TBL] [Abstract][Full Text] [Related]
15. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
16. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A as serum marker of pituitary adenomas.
Gussi IL; Young J; Baudin E; Bidart JM; Chanson P
Clin Endocrinol (Oxf); 2003 Nov; 59(5):644-8. PubMed ID: 14616890
[TBL] [Abstract][Full Text] [Related]
18. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.
Stridsberg M; Eriksson B; Oberg K; Janson ET
Regul Pept; 2004 Mar; 117(3):219-27. PubMed ID: 14749043
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
